A second player has officially arrived in the drug-eluting stent market with a European approval. Boston Scientific (BSX; Natick, Massachusetts) received the CE mark for its Taxus stent system in late January, joining Johnson & Johnson’s (J&J; New Brunswick, New Jersey) Cordis (Miami Lakes, Florida) unit in the still-elite coated-stent club.